Megan Sullivan
Clinical Operations Manager
Current Health
MelioLabs
Overview
MelioLabs transforms testing for infectious disease, beginning with a focus on the neonatal sepsis market.
The Issue
Neonatal sepsis kills 1 million newborns annually worldwide, and affects 1-2 cases per 1,000 live births in the U.S. alone. This fosters broad-spectrum antibiotic use that leads to poor outcomes and unnecessary costs associated with hospital stay and antibiotic overuse.
Approach
Rapid diagnosis would allow for quicker, more-targeted sepsis treatment for this vulnerable patient population, and this is where MelioLabs comes in. MelioLabs has developed a low-cost, universal platform to detect common pathogens and antibiotic resistance signatures directly from a patient sample in under 3 hours by machine-learning and digital melt analysis.
MTM Student Engagement
Our MTM team performed competitive market analysis, regulatory planning, data processing pipeline architecture design, creation of marketing materials, patent and freedom-to-operate analysis, species characterization, and reimbursement strategy.
Project Leader
MTM Team Members
Christine Rachel Joseph
Device Developer & Human Factors Engineer
Genentech
Diego Vieira
CSO & Co-Founder
Medical Harbour